Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 97 (10), e0091

The Clinical Significance of COL5A2 in Patients With Bladder Cancer: A Retrospective Analysis of Bladder Cancer Gene Expression Data

Affiliations

The Clinical Significance of COL5A2 in Patients With Bladder Cancer: A Retrospective Analysis of Bladder Cancer Gene Expression Data

Xian-Tao Zeng et al. Medicine (Baltimore).

Abstract

The present study was aimed to investigate the relationship between the expression of collagen type V alpha 2 chain (COL5A2) and clinical outcomes of patients with bladder cancer.Chi-square test and log-rank-based survival analysis were performed to assess the correlation of COL5A2 expression with clinical characteristics and survivals of patients with bladder cancer using GSE13507. Gene set enrichment analysis was conducted to study the relevant mechanisms.Bladder cancer patients in COL5A2 low expression group were associated with better invasiveness (P < .0001), tumor grade (P = .001), T staging (P < .0001), N staging (P = .002), cancer specific survival (P < .0001), overall survival (P < .0001), and a trend of better M staging (P = .053) than those in COL5A2 high expression group.COL5A2 might affect the progression of bladder cancer through "Coagulation," "Hypoxia," "Apical junction," "Ultraviolet response," "Epithelial mesenchymal transition," "Angiogenesis," "KRAS (KRAS proto-oncogene, GTPase) signaling,""Complement,""IL2-STAT5-signaling," "Inflammatory response," "IL6-JAK-STAT3-signaling," "Myogenesis," "TNF α signaling," "Apoptosis," and "Hedgehog-signaling."Our results demonstrated that COL5A2 was correlated with poor clinical outcomes and survivals of patients with bladder cancer, suggesting that it could be regarded as a biomarker of bladder cancer.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
The cancer specific survival (A) and overall survival (B) of bladder cancer patients in COL5A2 low expression group and COL5A2 high expression group. COL5A2 = collagen type V alpha 2 chain.

Similar articles

See all similar articles

Cited by 7 PubMed Central articles

See all "Cited by" articles

References

    1. Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017;71:96–108. - PubMed
    1. Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int 2017;119:371–80. - PMC - PubMed
    1. Pang C, Guan Y, Li H, et al. Urologic cancer in China. Jpn J Clin Oncol 2016;46:497–501. - PubMed
    1. Matsuda T, Okuyama A. Incidence rate for bladder cancer in Japanese in Japan and in the United States from the cancer incidence in five continents. Jpn J Clin Oncol 2017;47:284–5. - PubMed
    1. Kukreja JB, Shah JB. Advances in surgical management of muscle invasive bladder cancer. Indian J Urol 2017;33:106–10. - PMC - PubMed
Feedback